Bartalena L, Chiovato L, Vitti P
Endocrine Unit, Department of Clinical and Experimental Medicine, ASST dei Sette Laghi, Ospedale di Circolo, University of Insubria, Viale Borri, 57, Varese, Italy.
Fondazione Salvatore Maugeri and University of Pavia, Pavia, Italy.
J Endocrinol Invest. 2016 Oct;39(10):1105-14. doi: 10.1007/s40618-016-0505-x. Epub 2016 Jun 18.
Graves' disease is the most common cause of hyperthyroidism in iodine-replete areas. Although progress has been made in our understanding of the pathogenesis of the disease, no treatment targeting pathogenic mechanisms of the disease is presently available. Therapies for Graves' hyperthyroidism are largely imperfect because they are bound to either a high rate of relapsing hyperthyroidism (antithyroid drugs) or lifelong hypothyroidism (radioiodine treatment or thyroidectomy). Aim of the present article is to offer a practical guidance to the reader by providing evidence-based answers to frequently asked questions in clinical practice.
在碘充足地区,格雷夫斯病是甲状腺功能亢进最常见的病因。尽管我们对该疾病的发病机制的理解已取得进展,但目前尚无针对该疾病致病机制的治疗方法。格雷夫斯甲亢的治疗方法在很大程度上并不完美,因为它们要么会导致甲亢复发率高(抗甲状腺药物),要么会导致终身甲状腺功能减退(放射性碘治疗或甲状腺切除术)。本文的目的是通过为临床实践中常见问题提供循证答案,为读者提供实用指导。